Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Diabetologia
Erschienen in: Diabetologia 5/2011

01.05.2011 | Article

Calcium/calmodulin-dependent kinase IV controls glucose-induced Irs2 expression in mouse beta cells via activation of cAMP response element-binding protein

verfasst von: S. J. Persaud, B. Liu, H. Barbosa Sampaio, P. M. Jones, D. S. Muller

Erschienen in: Diabetologia | Ausgabe 5/2011

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

Irs2, which is upregulated by glucose, is important for beta cell plasticity. Cyclic AMP response element-binding protein (CREB) stimulates beta cell Irs2 expression and is a major calcium/calmodulin-dependent kinase (CaMK)IV target in neurons. We therefore hypothesised that CaMKIV mediates glucose-induced Irs2 expression in beta cells via CREB activation.

Methods

The functions of CaMKIV and CREB were investigated in MIN6 beta cells and mouse islets using the CaMK inhibitor KN62, the calcium chelator bapta-(AM) and the voltage-dependent calcium channel inhibitor nifedipine. Small interfering RNAs were used to silence endogenous CaMKIV production and expression vectors to overproduce constitutively active and dominant negative forms of CaMKIV and CREB. Irs1 and Irs2 expression were determined by quantitative PCR and Western blotting, and the role of CREB was also investigated by assessing its phosphorylation on serine 133.

Results

Increasing the glucose concentration from 2.5 to 25 mmol/l stimulated CREB phosphorylation on serine 133 and specifically stimulated Irs2 but not Irs1 expression. Similarly, overproduction of a constitutively active form of CaMKIV promoted sustained CREB phosphorylation and a significant increase in Irs2 but not Irs1 expression. In contrast, these stimulatory effects of glucose were all suppressed by overproducing an inactive CaMKIV mutant. Inhibition of glucose-induced calcium influx with nifedipine or chelation of intracellular calcium with bapta-(AM), as well as silencing of CaMKIV or inhibition of its activity with KN62 resulted in similar observations. Finally, overproduction of a dominant negative form of CREB completely suppressed glucose and CaMKIV stimulation of Irs2 expression.

Conclusions/interpretation

Our results suggest that the Ca2+/CaMKIV/CREB cascade plays a critical role in the regulation of Irs2 expression in beta cells.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Kahn SE (2001) Beta cell failure: causes and consequences. Int J Clin Pract 123:13–18
2.
Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC (2003) Beta cell deficit and increased beta cell apoptosis in humans with type 2 diabetes. Diabetes 52:102–110PubMedCrossRef
3.
Deng S, Vatamaniuk M, Huang X et al (2004) Structural and functional abnormalities in the islets isolated from type 2 diabetic subjects. Diabetes 53:624–632PubMedCrossRef
4.
Muoio DM, Newgard CB (2008) Mechanisms of disease: molecular and metabolic mechanisms of insulin resistance and beta cell failure in type 2 diabetes. Nat Rev Mol Cell Biol 9:193–205PubMedCrossRef
5.
Kahn SE, Carr DB, Faulenbach MV, Utzschneider KM (2008) An examination of beta cell function measures and their potential use for estimating beta cell mass. Diabetes Obes Metab 4:63–76CrossRef
6.
Chiasson JL, Rabasa-Lhoret R (2004) Prevention of type 2 diabetes: insulin resistance and beta cell function. Diabetes 53:S34–S38PubMedCrossRef
7.
Polonsky KS (2000) Dynamics of insulin secretion in obesity and diabetes. Int J Obes Relat Metab Disord 2:S29–S31
8.
Buchanan (2001) Pancreatic B-cell defects in gestational diabetes: implications for the pathogenesis and prevention of type 2 diabetes. J Clin Endocrinol Metab 86:989–993PubMedCrossRef
9.
Butler AE, Janson J, Soeller WC, Butler PC (2003) Increased beta cell apoptosis prevents adaptive increase in beta cell mass in mouse model of type 2 diabetes: evidence for role of islet amyloid formation rather than direct action of amyloid. Diabetes 52:2304–2314PubMedCrossRef
10.
Hull RL, Kodama K, Utzschneider KM, Carr DB, Prigeon RL, Kahn SE (2005) Dietary-fat-induced obesity in mice results in beta cell hyperplasia but not increased insulin release: evidence for specificity of impaired beta cell adaptation. Diabetologia 48:1350–1358PubMedCrossRef
11.
Parsons JA, Brelje TC, Sorenson RL (1992) Adaptation of islets of Langerhans to pregnancy: increased islet cell proliferation and insulin secretion correlates with the onset of placental lactogen secretion. Endocrinology 130:1459–1466PubMedCrossRef
12.
Bonner-Weir S, Deery D, Leahy JL, Weir GC (1989) Compensatory growth of pancreatic beta cells in adult rats after short-term glucose infusion. Diabetes 38:49–53PubMedCrossRef
13.
Paris M, Bernard-Kargar C, Berthault MF, Bouwens L, Ktorza A (2003) Specific and combined effects of insulin and glucose on functional pancreatic beta cell mass in vivo in adult rats. Endocrinology 144:2717–2727PubMedCrossRef
14.
Teil GM, Trivedi N, Jonas JC et al (2001) Adaptation of beta cell mass to substrate oversupply: enhanced function with normal gene expression. Am J Physiol Endocrinol Metab 280:E788–E796
15.
Muller D, Jones PM, Persaud SJ (2006) Autocrine anti-apoptotic and proliferative effects of insulin in pancreatic beta cells. FEBS Lett 580:6977–6980PubMedCrossRef
16.
Aikin R, Hanley S, Maysinger D et al (2006) Autocrine insulin action activates Akt and increases survival of isolated human islets. Diabetologia 49:2900–2909PubMedCrossRef
17.
Amacker-Francoys I, Mohanty S, Niessen M, Spinas GA, Trub T (2005) The metabolisable hexoses d-glucose and d-mannose enhance the expression of IRS-2 but not of IRS-1 in pancreatic beta cells. Exp Clin Endocrinol Diabetes 113:423–429PubMedCrossRef
18.
Lingohr MK, Briaud I, Dickson LM et al (2006) Specific regulation of IRS-2 expression by glucose in rat primary pancreatic islet beta cells. J Biol Chem 281:15884–15892PubMedCrossRef
19.
Kubota N, Tobe K, Terauchi Y et al (2000) Disruption of insulin receptor substrate 2 causes type 2 diabetes because of liver insulin resistance and lack of compensatory beta cell hyperplasia. Diabetes 49:1880–1889PubMedCrossRef
20.
Withers DJ, Gutierrez JS, Towery H et al (1998) Disruption of IRS-2 causes type 2 diabetes in mice. Nature 391:900–904PubMedCrossRef
21.
Hennige AM, Burks DJ, Ozcan U et al (2003) Upregulation of insulin receptor substrate-2 in pancreatic beta cells prevents diabetes. J Clin Invest 112:1521–1532PubMed
22.
Park S, Dong X, Fisher TL et al (2006) Exendin-4 uses Irs2 signaling to mediate pancreatic beta cell growth and function. J Biol Chem 281:1159–1168PubMedCrossRef
23.
Redmond L, Kashani AH, Ghosh A (2002) Calcium regulation of dendritic growth via CaM kinase IV and CREB-mediated transcription. Neuron 34:999–1010PubMedCrossRef
24.
Yu X, Murao K, Sayo Y et al (2004) The role of calcium/calmodulin-dependent protein kinase cascade in glucose upregulation of insulin gene expression. Diabetes 53:1475–1481PubMedCrossRef
25.
Ban N, Yamada Y, Someya Y et al (2000) Activating transcription factor-2 is a positive regulator in CaM kinase IV-induced human insulin gene expression. Diabetes 49:1142–1148PubMedCrossRef
26.
Jhala US, Canettieri G, Screaton RA et al (2003) cAMP promotes pancreatic beta cell survival via CREB-mediated induction of IRS2. Genes Dev 17:1575–1580PubMedCrossRef
27.
King A, Lock J, Xu G, Bonner-Weir S, Weir GC (2005) Islet transplantation outcomes in mice are better with fresh islets and exendin-4 treatment. Diabetologia 48:2074–2079PubMedCrossRef
28.
Papadimitriou A, King AJ, Jones PM, Persaud SJ (2007) Anti-apoptotic effects of arachidonic acid and prostaglandin E2 in pancreatic beta cells. Cell Physiol Biochem 20:607–616PubMedCrossRef
29.
30.
Muller D, Huang GC, Amiel S, Jones PM, Persaud SJ (2006) Identification of insulin signaling elements in human beta cells: autocrine regulation of insulin gene expression. Diabetes 55:2835–2842PubMedCrossRef
31.
Sun P, Lou L, Maurer RA (1996) Regulation of activating transcription factor 1 and the cAMP response element-binding protein by Ca2+/calmodulin-dependent protein kinases type I, II, and IV. J Biol Chem 271:3066–3073PubMedCrossRef
32.
Murray PD, Kingsbury TJ, Krueger BK (2009) Failure of Ca(2+)-activated, CREB-dependent transcription in astrocytes. Glia 57:828–834PubMedCrossRef
33.
Ho N, Liauw JA, Blaeser F et al (2000) Impaired synaptic plasticity and cAMP response element-binding protein activation in Ca2+/calmodulin-dependent protein kinase type IV/Gr-deficient mice. J Neurosci 20:6459–6472PubMed
34.
Hansen MR, Bok J, Devaiah AK, Zha XM, Green SH (2003) Ca2+/calmodulin-dependent protein kinases II and IV both promote survival but differ in their effects on axon growth in spiral ganglion neurons. J Neurosci Res 72:169–184PubMedCrossRef
35.
Yano S, Tokumitsu H, Soderling TR (1998) Calcium promotes cell survival through CaM-K kinase activation of the protein-kinase-B pathway. Nature 396:584–587PubMedCrossRef
36.
Sée V, Boutillier AL, Bito H, Loeffler JP (2001) Calcium/calmodulin-dependent protein kinase type IV (CaMKIV) inhibits apoptosis induced by potassium deprivation in cerebellar granule neurons. FASEB J 15:134–144PubMedCrossRef
37.
Deisseroth K, Heist EK, Tsien RW (1998) Translocation of calmodulin to the nucleus supports CREB phosphorylation in hippocampal neurons. Nature 392:198–202PubMedCrossRef
38.
Jansson D, Ng ACH, Fu A, Depatie C, Al Azzabi M, Screaton RA (2008) Glucose controls CREB activity in islet cells via regulated phosphorylation of TORC2. Proc Natl Acad Sci U S A 105:10161–10166PubMedCrossRef
39.
Pechhold K, Koczwara K, Zhu X et al (2009) Blood glucose levels regulate pancreatic beta cell proliferation during experimentally-induced and spontaneous autoimmune diabetes in mice. PLos ONE 4:e4827PubMedCrossRef
40.
Bonner-Weir S (1994) Regulation of pancreatic beta cell mass in vivo. Recent Prog Horm Res 49:91–104PubMed
41.
Hoorens A, Van de CM, Kloppel G, Pipeleers D (1996) Glucose promotes survival of rat pancreatic beta cells by activating synthesis of proteins which suppress a constitutive apoptotic program. J Clin Invest 98:1568–1574PubMedCrossRef
42.
Enslen H, Sun P, Brickey D, Soderling SH, Klamo E, Soderling TR (1994) Characterization of Ca2+/calmodulin-dependent protein kinase IV: role in transcriptional regulation. J Biol Chem 269:15520–15527PubMed
43.
Landa LR Jr, Harbeck M, Kaihara K et al (2005) Interplay of Ca2+ and cAMP signalling in the insulin-secreting MIN6 β-cell line. J Biol Chem 280:31294–31302PubMedCrossRef
44.
Ishihara H, Asano T, Tsukuda K et al (1993) Pancreatic beta cell line MIN6 exhibits characteristics of glucose metabolism and glucose-stimulated insulin secretion similar to those of normal islets. Diabetologia 36:1139–1145PubMedCrossRef
45.
Arrázola MS, Varela-Nallar L, Colombres M et al (2009) Calcium/calmodulin-dependent protein kinase type IV is a target gene of the Wnt/beta-catenin signaling pathway. J Cell Physiol 221:658–667PubMedCrossRef
46.
Jin T, Liu L (2008) The Wnt signalling pathway effector TCF7L2 and type 2 diabetes mellitus. Mol Endocrinol 22:2383–2392PubMedCrossRef
47.
48.
Liu Z, Habener JF (2008) Glucagon-like peptide-1 activation of TCF7L2-dependent Wnt signaling enhances pancreatic beta cell proliferation. J Biol Chem 283:8723–8735PubMedCrossRef
49.
Loder MK, da Silva XG, McDonald A, Rutter GA (2008) TCF7L2 controls insulin gene expression and insulin secretion in mature pancreatic beta cells. Biochem Soc Trans 36:357–359PubMedCrossRef
Metadaten
Titel
Calcium/calmodulin-dependent kinase IV controls glucose-induced Irs2 expression in mouse beta cells via activation of cAMP response element-binding protein
verfasst von
S. J. Persaud
B. Liu
H. Barbosa Sampaio
P. M. Jones
D. S. Muller
Publikationsdatum
01.05.2011
Verlag
Springer-Verlag
Erschienen in
Diabetologia / Ausgabe 5/2011
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-011-2050-7

Weitere Artikel der Ausgabe 5/2011

Diabetologia 5/2011 Zur Ausgabe

Commentary

Risk scores for predicting type 2 diabetes: comparing axes and spades

Article

Low transition rate from normo- and low microalbuminuria to proteinuria in Japanese type 2 diabetic individuals: the Japan Diabetes Complications Study (JDCS)

Article

Receptor for advanced glycation end-products (RAGE) provides a link between genetic susceptibility and environmental factors in type 1 diabetes

Article

A low frequency of pancreatic islet insulin-expressing cells derived from cord blood stem cell allografts in humans

Article

Diabetes mellitus and incidence of kidney cancer: a meta-analysis of cohort studies

Article

Glucose oscillations, more than constant high glucose, induce p53 activation and a metabolic memory in human endothelial cells

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise